Xcout Intel
Vogenx, Inc.
Vogenx, Inc. is a clinical-stage biopharmaceutical and life science company that discovers and develops novel therapeutics to treat metabolic and gastrointestinal diseases, including post-bariatric hypoglycemia and gastroparesis. Its lead drug candidate, mizagliflozin, is an oral small molecule designed to inhibit SGLT1, reducing glucose absorption and the secretion of insulin and gastric inhibitory peptide.
Subscribe to see Vogenx, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Vogenx, Inc. at a glance
Vogenx, Inc. is a biotech company headquartered in Raleigh, United States. Xcout tracks 11 named people at Vogenx, Inc., including James Green (President, CEO & Chairman).
Vogenx, Inc. leadership
- James GreenPresident, CEO & Chairman
- Steven R. DelmarCFO, Corporate Secretary & Director
- Steven DelmarChief Financial Officer
- William WilkisonChief Scientific Officer, Chair of Scientific Advisory Board & Director
- James GreenExecutive Officer
- Steven DelmarExecutive Officer
5 more named people on record for Vogenx, Inc., with roles, board committees and tenure — see the full roster →
Vogenx, Inc. funding rounds before its IPO
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $11M | — |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Vogenx, Inc. news
- IPOVogenx (proposed Nasdaq: VOGX) IPO aims to lift cash to ...
- IPOVogenx Inc Common Stock IPO on NASDAQ
- IPOIPO registration (S-1)
- IPOA small drug company based in Raleigh is targeting the public ...
6 corporate events on record, with sources — see the full timeline →
Vogenx, Inc. competitors
A few of Vogenx, Inc.'s closest competitors — see the full list of competitors and alternatives →
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
Aclipse Therapeutics is a clinical-stage biopharmaceutical company that develops novel, disease-modifying drug candidates for severe and life-threatening conditions such as gastroparesis and amyotrophic lateral sclerosis (ALS). The company leverages genomic, proteomic, and biomarker data to target molecular pathways involving inflammation, cellular stress, and protein misfolding, while also implementing patient stratification approaches to improve clinical outcomes.
Syntis Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, dedicated to revolutionizing oral therapies for obesity and metabolic diseases.
DiogenX is a preclinical-stage biotechnology company headquartered in Marseille, France, with research laboratories in Nice, dedicated to developing novel treatments for diabetes.
Guangzhou Innogen Pharmaceutical Group Co Ltd operates as a China-based investment holding firm with a core mission to research, develop, and bring to market medicinal products. The company specializes in producing innovative, human-compatible, and extended-duration GLP-1 receptor agonists, specifically targeting the treatment of diabetes and other metabolic conditions.
Get Vogenx, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Vogenx, Inc. in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- 1 funding round before the IPO with the investors in each, and who they co-invest with
- 6 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access